ANGANY Appoints Christine Guillen as CEO, Announces Strengthening of Its Executive Committee
02 Nov 2023
Executive ChangeImmunotherapy
ANGANY expands and redefines its executive team to better manage upcoming development stages.
QUEBEC CITY--(BUSINESS WIRE)-- ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer. In this capacity, Ms. Guillen will sit on the Board of Directors.
ANGANY also announces the strengthening of its Executive Committee with the appointment of Mr. Patrick Colin, BPharm PhD, as Vice-President, Clinical Development, and Pr. Claude Favrot, DMV, as Vice-President, Veterinary Development.
A pharmacist by training, Ms. Guillen brings with her a solid expertise in biopharmaceuticals, as well as extensive experience in managing innovative life sciences companies. She joins the ANGANY team as the company reaches a turning point. With the start of clinical development of its next-generation biologic ANG-101 for the treatment of cat allergy, ANGANY must evolve its programs and operations. Ms. Guillen's structured approach will accelerate the achievement of value milestones on ANGANY’s timetable.
Ms. Guillen says: "I'm delighted to take up the challenge of bringing a breakthrough technology to a tangible clinical and pharmaceutical reality. We are privileged to have been able to recruit Patrick Colin and Claude Favrot, each an authority in his field through their respective competence and experience."
Former CEO Louis-Philippe Vézina was instrumental in recruiting his successor. He has been appointed Executive Chairman of the Board.
About ANGANY
ANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy through breakthrough therapeutics. ANGANY’s eBioparticle™ technology makes for biologics of a new generation to be administered as vaccines. The goal is to restore or reinforce natural immune mechanisms and create lasting immune protection. ANGANY's eBioparticle-Potentiated Immunotherapy™ also opens-up new prospects in several fields of application beyond allergy in human and animal health, notably in cancer immunotherapy. The company operates a cGMP pilot production unit in Quebec, as well as an R&D laboratory in France. ANGANY uses a flexible, efficient and easily scalable 3rd generation plant bioproduction platform to manufacture its next-generation biologics.
For more information: ANGANY
View source version on businesswire.com:
Contacts
Medias and investor relations:
Guy Tropper MD FRCSC
Co-Founder and Executive Vice-President
guy.tropper@angany.com
Source: ANGANY
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.